Navigation Links
Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously
Date:5/20/2010

SAN FRANCISCO and WASHINGTON, May 20 /PRNewswire/ -- Jennerex, Inc., a clinical-stage cancer biotherapeutics company, today reported positive results from its Phase 1 dose escalation study evaluating the intravenous (IV) administration of JX-594 to patients with metastatic cancer.  The data presented today demonstrated clear dose-related delivery to solid tumors, cancer-targeted replication and gene expression, and anti-cancer effects of JX-594 delivered IV.  Choi (necrotic) responses were more commonly observed in patients treated at higher doses.  In addition, intravenous infusion of JX-594 was safe and well-tolerated.  These data were presented today at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting in Washington DC.

"These data represent a significant milestone for the field of oncology and viral therapy as this is the first time that a viral or genetic product has demonstrated reproducible, biopsy-proven delivery to multiple solid tumor types following intravenous administration," said David H. Kirn, M.D., president and chief executive officer of Jennerex.  "We look forward to extending our experience with IV JX-594 in our planned Phase 3 trial in patients with advanced liver cancer.  This pivotal trial will utilize both IV and targeted intratumoral injections of JX-594 to maximize potential patient benefit.  We expect to initiate this study in Q4 of 2010."

"JX-594 represents a promising potential treatment option for patients with multiple types of cancer.  As the first intravenous biological immunotherapy to demonstrate safety and tumor-specific delivery, JX-594 may add significantly to the armamentarium for many solid tumors," stated '/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Jennerex Appoints Bob Ingram Special Advisor and Hires Marty Glick as EVP, Corporate Strategy
2. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
3. Jennerex Appoints Samantha Miller as Vice President of Corporate Development
4. Nature Reviews Publishes Article About Jennerexs Multi-Mechanistic Cancer Therapeutic
5. Jennerex Closes $5 Million First Tranche of Series C Financing
6. Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
7. Jennerex Adds Industry Veteran Paul Cleveland to Board of Directors
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. QMed, Inc. Reports July Medicare SNP Enrollments
10. Phlo Affiliate Reports Expanded Coverage to Oregon Border
11. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... 2015  Eli Lilly and Company (NYSE: LLY ... cancer therapies, reflecting Lilly,s diverse oncology pipeline, during the ... held April 18-22 in Philadelphia , ... is the theme of this year,s AACR meeting and ... its portfolio of therapies that accelerate the pace and ...
(Date:4/20/2015)... Sinovac Biotech Ltd. (Nasdaq: SVA), a leading ... unaudited financial results for the fourth quarter and full ... 2014 Financial Highlights(Compared to the fourth quarter 2013) ... of 11.4% from $22.9 million in the prior year ... pandemic influenza vaccine of $0.1 million in the fourth ...
(Date:4/18/2015)... PHILADELPHIA , April 18, 2015 ... (NASDAQ: CRIS ) will be presenting data ... the American Associate of Cancer Research Annual Meeting ... ).      (Logo: http://photos.prnewswire.com/prnh/20130418/608115 ) ... its proprietary Nicotinamide phosphoribosyltransferase (NAMPT) small molecule inhibitors ...
(Date:4/17/2015)... 17, 2015 /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: SQD; ... that develops and commercializes proprietary technologies and products ... it has received approval from the TSX Venture ... common share purchase warrants ("the Warrants") of the ... Company,s May 2013 private placement financing. ...
Breaking Biology Technology:Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 2Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 3Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 4Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 5Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 6Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 2Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 3Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 4Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 5Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 6Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 7Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 8Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 9Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 10Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 11Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 12Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 13Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 14Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 15Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 16Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 17Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 18Aurigene to Present its NAMPT and IRAK-4 Inhibitors Programs at AACR 2015 2SQI Diagnostics to Extend Warrant Expiry 2SQI Diagnostics to Extend Warrant Expiry 3
... , a provider of molecular diagnostics solutions, reported losses in ... Wave reported total revenue of $5.8 million and a net ... for the quarter ended June 30, 2005, compared to total ... and zero cents per diluted share for the same period ...
... Third Wave Technologies Inc., a developer and provider ... chairman of the company's board of directors, replacing company ... the business's planned transition. , ,Thompson, 63, was the ... of Abbott Laboratories , an Illinois-based medical products ...
... Corp ., a Waukesha-based supply chain technology ... enabling Cooper Lighting , a George-based ... distribution operations and workforce productivity. , ,The ... with RedPrairie's DLx Warehouse, slotting and workforce ...
Cached Biology Technology:Transition continues to impact Third Wave financials 2
(Date:4/2/2015)... Fingerprint Cards (FPC) has received ... the distributor World Peace Industrial Group (WPI), part of ... the major part of the shipments will take place ... smartphone manufacturers in China . The ... communicated revenue guidance of + 1 000 MSEK for 2015.  ...
(Date:3/30/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/lc9bnl/global_gesture ) has ... Market in Automotive Sector 2014-2018" report to their ... Recognition market in Automotive Sector to grow at a ... Gesture recognition is the ability of a device to ... Gesture recognition technology can be 2D-based or 3D-based. It ...
(Date:3/24/2015)... GARDENS, Fla. , March 24, 2015 /PRNewswire/ ... identity management solutions, today announced that its U.are.U ... clothing accessory retailer Goorin Bros . to ... Crossmatch biometrics-based solution secures access to the POS ... the increased risk of data breaches. ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2
... of a new gene is helping researchers at Michigan ... A team of researchers, led by Katherine Osteryoung, ... a new class of proteins in the ... Academy of Sciences . CLMP1 plays a key role ...
... aid cavity-nesting ducks can prove to be turtle death traps. ... Educator Associate Professor Denis Conover, of the Department of Biological ... he came upon a duck nest box in the wetlands ... over. Turtle corpses were strewn about the mud and mire ...
... living in family or group homes are less ... living in institutions, according to University of Louisville ... Ph.D. These individuals also are more likely than ... increased decay and gum disease, factors that may ...
Cached Biology News:Discovery of new gene could improve efficiency of molecular factories 2UC research finds that a duck's boon might be a turtle's bane 2UofL researcher to develop oral health plan for those with IDD 2